1. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models. Issue 2 (20th October 2016) Authors: Politz, Oliver; Siegel, Franziska; Bärfacker, Lars; Bömer, Ulf; Hägebarth, Andrea; Scott, William J.; Michels, Martin; Ince, Stuart; Neuhaus, Roland; Meyer, Kirstin; Fernández‐Montalván, Amaury Ernesto; Liu, Ningshu; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbauer, Karl Journal: International journal of cancer Issue: Volume 140:Issue 2(2017:Jan. 15) Page Start: 449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. (16th October 2017) Authors: Lücking, Ulrich; Scholz, Arne; Lienau, Philip; Siemeister, Gerhard; Kosemund, Dirk; Bohlmann, Rolf; Briem, Hans; Terebesi, Ildiko; Meyer, Kirstin; Prelle, Katja; Denner, Karsten; Bömer, Ulf; Schäfer, Martina; Eis, Knut; Valencia, Ray; Ince, Stuart; von Nussbaum, Franz; Mumberg, Dominik; Ziegelbau... Journal: ChemMedChem Issue: Volume 12:Number 21(2017) Page Start: 1776 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. Issue 5 (13th March 2019) Authors: Grünewald, Sylvia; Politz, Oliver; Bender, Sebastian; Héroult, Mélanie; Lustig, Klemens; Thuss, Uwe; Kneip, Christoph; Kopitz, Charlotte; Zopf, Dieter; Collin, Marie‐Pierre; Boemer, Ulf; Ince, Stuart; Ellinghaus, Peter; Mumberg, Dominik; Hess‐Stumpp, Holger; Ziegelbauer, Karl Journal: International journal of cancer Issue: Volume 145:Issue 5(2019) Page Start: 1346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗